Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
By V. Galimberti, B. Cole, S. Zurrida, G. Viale, A. Luini, P. Veronesi, P. Baratella, C. Chifu, M. Sargenti, M. Intra and 17 more. The Lancet Oncology, 2013
1,193 citations recorded by the source corpus.
Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/5c70496b548d20f686bb4fa4970166cee5e44224
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. (2014, methodology): “In the four studies reporting these,5,6,11,13,20,21 the percentages of patients experiencing these deficits were statistically significantly lower in the SNB-alone arms.5,6,11,18,20 For example, residual arm tingling and numbness at 36 months were significantly lower in favor of SNB. Rates of sensor”
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013, background): “Thus, axillary dissection can safely be omitted for patients with micrometastatic disease in sentinel nodes [65] and for those undergoing breast-conserving surgery and whole breast radiation therapy with up to two macroscopically positive sentinel nodes [66] (Table 1).”